Reaktionsgleichung
Cl[CH2:2][C:3]([N:5]1[C:11]2[CH:12]=[CH:13][CH:14]=[CH:15][C:10]=2[C:9](=[O:16])[NH:8][C:7]2[CH:17]=[CH:18][CH:19]=[N:20][C:6]1=2)=[O:4].[CH3:21][O:22][C:23]1[CH:32]=[CH:31][C:26]([CH2:27][CH2:28]CN)=[CH:25][CH:24]=1.C(=O)([O-])O.[Na+].[C:38](#[N:40])C>>[CH3:21][O:22][C:23]1[CH:24]=[CH:25][C:26]([CH2:27][CH2:28][N:40]([CH2:2][C:3]([N:5]2[C:11]3[CH:12]=[CH:13][CH:14]=[CH:15][C:10]=3[C:9](=[O:16])[NH:8][C:7]3[CH:17]=[CH:18][CH:19]=[N:20][C:6]2=3)=[O:4])[CH3:38])=[CH:31][CH:32]=1Komponenten
5
Edukt 4
Produkt 1
Versuchsvorschrift
A mixture of 11-chloroacetyl-5,11-dihydro-6H-pyrido- [2,3-b][1,4]benzodiazepine-6-one (288 mg) (German patent 1,936,670), N-(4-methoxyphenethyl)methylamine (182 mg) and sodium hydrogen carbonate (92 mg) in acetonitrile (25 ml) was heated under reflux for 16 hours and evaporated. The residue was partitioned between 2M aqueous sodium hydrogen carbonate solution and dichloromethane and the organic layer washed with brine, dried over MgSO4 and evaporated. The residue was purified by chromatography on silica using dichloromethane plus 0-10% methanol as eluant. Appropriate fractions were combined and evaporated and the residue crystallised from ethyl acetate to give the title compound as a colourless solid, 216 mg (52%).
Aufarbeitung
- temperaturewas heated
- temperatureunder reflux for 16 hours
- customevaporated
- customThe residue was partitioned between 2M aqueous sodium hydrogen carbonate solution and dichloromethane
- washthe organic layer washed with brine
- dry with materialdried over MgSO4
- customevaporated
- customThe residue was purified by chromatography on silica
- customevaporated
- customthe residue crystallised from ethyl acetate
Quellen und Nachweise
- ORD-Eintrag
- ord-80d480d22c604362833a5a9a03047339
- Quelldatensatz
- uspto-grants-1995_05
- Patentnummer
- US05418229
Verknüpfte Notizen
Wird geladen…